Abstract
Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be confirmed in randomized controlled studies.
Publication types
-
Clinical Trial
-
Letter
-
Randomized Controlled Trial
MeSH terms
-
Blood Transfusion
-
Erythropoietin / adverse effects*
-
Ferric Compounds / adverse effects*
-
Ferritins / blood
-
Hematocrit
-
Humans
-
Incidence
-
Infant, Newborn
-
Recombinant Proteins
-
Respiratory Distress Syndrome, Newborn / therapy
-
Retinopathy of Prematurity / classification
-
Retinopathy of Prematurity / diagnosis
-
Retinopathy of Prematurity / etiology*
-
Severity of Illness Index
Substances
-
Ferric Compounds
-
Recombinant Proteins
-
Erythropoietin
-
Ferritins
-
teferrol